GeneDx (NASDAQ:WGS – Get Free Report) and Auna (NYSE:AUNA – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Institutional and Insider Ownership
61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
GeneDx has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Auna has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 1 | 3 | 7 | 0 | 2.55 |
| Auna | 1 | 3 | 1 | 0 | 2.00 |
GeneDx presently has a consensus price target of $129.22, indicating a potential downside of 7.52%. Auna has a consensus price target of $10.70, indicating a potential upside of 97.60%. Given Auna’s higher possible upside, analysts clearly believe Auna is more favorable than GeneDx.
Profitability
This table compares GeneDx and Auna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | 0.52% | 20.22% | 11.89% |
| Auna | 5.49% | 15.14% | 3.60% |
Earnings & Valuation
This table compares GeneDx and Auna”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $402.19 million | 9.98 | -$52.29 million | $0.09 | 1,552.56 |
| Auna | $1.17 billion | 0.34 | $29.39 million | $0.88 | 6.15 |
Auna has higher revenue and earnings than GeneDx. Auna is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Summary
GeneDx beats Auna on 8 of the 14 factors compared between the two stocks.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
About Auna
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
